Dominican Republic vs Puerto Rico: Manufacturing and U.S. Market Access Comparison

Puerto Rico’s Key Advantages

As a U.S. territory, Puerto Rico-manufactured goods are not subject to import duties and require no CAFTA-DR origin documentation — they are domestic U.S. goods. For pharmaceutical manufacturers requiring FDA manufacturing in U.S. jurisdiction, or medical device companies where U.S. domestic manufacture is required by contract or regulation, Puerto Rico resolves compliance constraints the Dominican Republic cannot. Puerto Rico’s Act 60 incentives offer a 4% corporate rate on export income — higher than the DR’s zero, but far below mainland U.S. rates.

Dominican Republic’s Key Advantages

The Dominican Republic’s Law 8-90 free zone exemptions provide complete income tax elimination versus Puerto Rico’s 4% Act 60 rate. Manufacturing labor costs in the DR ($3–5/hr) are significantly lower than Puerto Rico ($12–18/hr for manufacturing roles). For foreign companies — particularly from the Middle East and Europe — that do not require U.S. territory jurisdiction, the DR’s cost structure is substantially more competitive.

The Regulatory Consideration

Puerto Rico’s FDA and federal regulatory equivalence with the U.S. mainland is a significant advantage for pharmaceutical and complex medical device manufacturers. The DR requires FDA foreign establishment registration — workable for most medical device and food categories, but not equivalent to domestic U.S. manufacture for all regulatory purposes.

Which to Choose

Puerto Rico: for pharmaceutical manufacturing, IP holding structures benefiting from U.S. territory treatment, or operations where U.S. domestic manufacture is contractually or regulatorily required. Dominican Republic via the Caribbean Corridor: for foreign manufacturers targeting the U.S. market who do not require U.S. territory jurisdiction and where cost efficiency is the primary variable. Contact EGS to assess the right structure for your mandate.